Design and antiviral assessment of a panel of fusion proteins targeting human papillomavirus type 16.
Cervical cancer ranks as the third most prevalent malignancy in women worldwide. The persistence of Human papillomavirus (HPV) infection stands out as the foremost risk factor for cervical cancer development. Among the numerous HPV subtypes, HPV16 infection emerges as the primary pathogenic determin...
Saved in:
| Main Authors: | Chongzhi Bai, Ruoyu Wang, Qian Yang, Jianqing Hao, Qiming Zhong, Ruiwen Fan, Pengcheng Han |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2024-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0311137 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Virtual screening of antiviral peptides as novel blockers of human papillomavirus 16
by: H. Al-Madhagi
Published: (2024-10-01) -
Human papillomavirus E2 proteins suppress innate antiviral signaling pathways
by: Jin-Xin Li, et al.
Published: (2025-04-01) -
Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies
by: Renee N Donahue, et al.
Published: (2020-10-01) -
Influence of Codon Bias on Heterologous Production of Human Papillomavirus Type 16 Major Structural Protein L1 in Yeast
by: Milda Norkiene, et al.
Published: (2012-01-01) -
Preclinical studies of antiviral activity of the RPH-137 fusion protein and molnupiravir against COVID-19
by: E. V. Shipaeva, et al.
Published: (2022-12-01)